- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
BSX
GER
Week ended 07 Aug 2026
Weekly Investor Report
Boston Scientific Corporation · Healthcare · Medical Devices
Latest close
42.94 EUR
9.6%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -18.6% below the Trend Line and sits at 10.6% of its 52-week range. The latest completed week returned 9.6%, after a 10.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100.
Setup score
29
out of 100
Latest Close
42.94 EUR
7 Aug 2026
1W Return
9.6%
latest completed week
4W Return
10.2%
short-term follow-through
12W Return
-6.0%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 40.28% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
9.6%
Latest completed week; four-week move 10.2%.
Indicator stack
0/66
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.28%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
49/100
32 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -18.6% below the Trend Line and sits at 10.6% of its 52-week range. The latest completed week returned 9.6%, after a 10.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.01
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.2% over four weeks, -6.0% over 12 weeks, and -51.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.26Latest activity-pressure read.
Pressure change136.1%Four-week change in activity pressure.
Leadership-40.66Latest relative-leadership reading.
RS change12.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength23/100Blend of value, momentum, and quality. Underlying universe rank 78; rank 1 is best.
Value33/100Relative valuation strength. Underlying universe rank 68; rank 1 is best.
Quality85/100Profitability and accounting quality. Underlying universe rank 16; rank 1 is best.
Momentum3/100Medium-term price momentum. Underlying universe rank 98; rank 1 is best.
Growth96/100Revenue and earnings growth. Underlying universe rank 5; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework58/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 17.5x Price divided by trailing earnings.
- Price / sales
- 3.0x Market value relative to trailing revenue.
- EV / EBITDA
- 13.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 69.2% Gross profit retained from each unit of revenue.
- Operating margin
- 19.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 16.0% Free cash flow generated from revenue.
- Return on invested capital
- 8.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 19.9% Latest one-year revenue growth.
- EPS growth
- 55.4% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 43.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment49/100
Weighted news tone is neutral across 32 relevant articles.
6 positive · 17 neutral · 9 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-53.7%Distance below the 52-week high.
13-week volatility6.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2617 weeks finished lower.
Best week+9.6%Week of 7 Aug.
Worst week-16.8%Week of 29 May.
Latest week+9.6%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains5
Flat weeks0
Modest losses11
Sharp losses6
Recent vol6.4%13-week weekly-return volatility.
Base vol4.9%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew2.9% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank12 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Medical Devices
4-week rank5 / 12
Group average7.0%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD75.0%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis12/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Next-Week ExpectancyNegative 40.28%Next-week expectancy is negative with a 40.28% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 58; Small Cap Core rank 80 SVQF58/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 159.0 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment49/100Weighted news tone is neutral across 32 relevant articles.
Boston Scientific (BSX) EVP boosts company stock stake through 401(k) rebalance Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 42.94 EUR | 9.6% | 52.76 EUR | 70.91 EUR | 0.26 | -40.66 | 7.8K | Off |
| 31 Jul 2026 | 39.18 EUR | -0.0% | 54.12 EUR | 70.93 EUR | 0.00 | -45.18 | 13.7K | Off |
| 24 Jul 2026 | 39.19 EUR | 1.6% | 55.51 EUR | 70.98 EUR | -0.28 | -44.88 | 6.1K | Off |
| 17 Jul 2026 | 38.57 EUR | -1.0% | 56.92 EUR | 71.04 EUR | -0.49 | -45.97 | 9.3K | Off |
| 10 Jul 2026 | 38.97 EUR | -2.1% | 58.37 EUR | 71.10 EUR | -0.72 | -46.69 | 11.6K | Off |
| 3 Jul 2026 | 39.80 EUR | 0.7% | 59.68 EUR | 71.15 EUR | -0.96 | -47.77 | 558 | Off |
| 26 Jun 2026 | 39.51 EUR | -1.2% | 61.17 EUR | 71.20 EUR | -1.03 | -46.58 | 626 | Off |
| 19 Jun 2026 | 40.00 EUR | -0.1% | 62.78 EUR | 71.27 EUR | -1.03 | -47.33 | 376 | Off |
| 12 Jun 2026 | 40.03 EUR | -7.0% | 64.26 EUR | 71.33 EUR | -0.98 | -47.28 | 1.6K | Off |
| 5 Jun 2026 | 43.02 EUR | 4.1% | 65.89 EUR | 71.39 EUR | -1.10 | -44.35 | 1.9K | Off |
| 29 May 2026 | 41.35 EUR | -16.8% | 67.34 EUR | 71.42 EUR | -1.23 | -47.88 | 15.1K | Off |
| 22 May 2026 | 49.72 EUR | 8.8% | 68.88 EUR | 71.47 EUR | -1.39 | -37.62 | 6.0K | Off |
| 15 May 2026 | 45.69 EUR | -2.7% | 70.15 EUR | 71.46 EUR | -1.54 | -41.11 | 3.8K | Off |
| 8 May 2026 | 46.95 EUR | -3.4% | 71.45 EUR | 71.48 EUR | -1.55 | -41.17 | 2.7K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.